Background
==========

Dyslipidemia, which is characterized by abnormally increased total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C) levels, is a well-established risk factor for cardiovascular diseases ([@ref-11]; [@ref-22]; [@ref-26]) and contributes to metabolic syndrome (MetS), stroke and other metabolism-related diseases ([@ref-1]; [@ref-2]; [@ref-37]; [@ref-42]). A nationally representative survey in China indicated that the prevalence of high TC, high LDL-C, low HDL-C and high TG in Chinese adults over the age of 18 was 6.9, 8.1, 20.4 and 13.8%, respectively ([@ref-48]). Previous studies involving epidemiological surveys found that diet, exercise and other environmental risk factors may be associated with abnormal serum lipid levels ([@ref-33]). However, genetic factors could also partially explain the development of dyslipidemia ([@ref-9], [@ref-10]; [@ref-38]).

The *APOA1/C3/A4/A5-ZPR1-BUD13* (APO, apolipoprotein; ZPR1, zinc finger; BUD13, BUD13 homolog) gene cluster is located on chromosome 11q23.3, and the apolipoprotein gene cluster at this location has been revealed to be more often associated with lipid traits via genome-wide association study (GWAS) ([@ref-6]; [@ref-39]). APOA1 synthesis and lipolysis promote HDL-mediated reverse cholesterol transport by generating cholesterol acceptors ([@ref-28]); therefore, APOA1 plays an important part in lipid metabolism, especially that of HDL cholesterol. The major function of APOC3 in lipid metabolism is to inhibit lipoprotein lipase (LPL); thus, the concentrations of plasma APOC3 are positively associated with TG concentrations ([@ref-21]). APOA4 modulates the activation of LPL by APOC2 ([@ref-15]) and participates in reverse cholesterol transport ([@ref-30]). The transcription of APOA4 is regulated synchronously with that of APOA1, supporting the relationship between these apolipoproteins ([@ref-19]) and APOA4 is associated with TG and HDL levels. APOA5 is a component of HDL and regulates TG levels via hydrolysis of TG-rich lipoproteins and endocytosis of lipoprotein remnants ([@ref-13]). *BUD13* encodes the BUD13 homolog protein, which is one of the subunits of the splicing factor that affects nuclear pre-mRNA retention ([@ref-7]). *ZPR1* encodes a regulatory protein involved in cell proliferation and signal transduction ([@ref-14]). In summary, based on the above mechanisms, this gene cluster can influence lipid levels, therapy contributing to the risk of dyslipidemia.

Relevant studies have been conducted to explore the relationship between serum lipid levels and genetic loci in this gene cluster among different ethnic groups ([@ref-3], [@ref-4]; [@ref-17]; [@ref-32]; [@ref-45]). However, to the best of our knowledge, there have been few studies conducted in northeast Chinese populations that explore the relationship between the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster and dyslipidemia. Functional single nucleotide polymorphism (SNP) may influence gene and protein expression. This study assessed the association of tag and well-studied SNPs (*APOA1* rs5072, *APOC3* rs5128, *APOA4* rs5104, *APOA5* rs651821, *ZPR1* rs2075294 and *BUD13* rs10488698) selected from the Han Chinese data in Haploview (<http://hapmap.ncbi.nlm.nih.gov/>) and based on previous studies ([@ref-41], [@ref-42]) with dyslipidemia in the overall sample and stratified by genders in a large sample from a Han Chinese population.

Materials and methods
=====================

Study population
----------------

The Project of Present Situation and Change Forecast of Disease Spectrum in Jilin Province, China, was conducted from June 2012 to August 2012 among individuals aged 18--79 years in all nine areas of Jilin Province. This project was a cross-sectional and representative survey of Jilin Province, China, which aimed to evaluate the prevalence and risk factors associated with chronic diseases ([@ref-36]). The genetic associations results for dyslipidemia-related diseases have been reported in previous studies ([@ref-31]; [@ref-47], [@ref-46]). The whole sample size of the survey was 21,435, and the participants in our present study were randomly chosen from the whole sample. They were unrelated members of the Han population, and individuals with a family history of dyslipidemia and other metabolic diseases or without complete serum lipid data were excluded; the participants were excluded if they were being treated with any drugs that may affect lipid parameters. In total, 3,850 participants (1,927 males and 1,923 females) were enrolled in the association study between the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster and dyslipidemia.

Dyslipidemia was assessed according to the Guidelines on Prevention and Treatment of Dyslipidemia in Chinese Adults ([@ref-25]): hypertriglyceridemia, TG ≥2.26 mmol/L; hypercholesterolemia, TC ≥6.22 mmol/L; hyper-LDL cholesterolemia, LDL-C ≥4.14 mmol/L; low-HDL cholesterolemia, HDL-C \<1.04 mmol/L.

For laboratory evaluation, including the assessment of total TC, TG, HDL-C and LDL-C levels, five mL blood samples were collected from each individual. The blood samples were transported under refrigeration and than stored at −20 °C. Our study was approved by the ethics committee of the Jilin University School of Public Health (2012-R-011), and all subjects in this study signed a written informed consent form.

SNP selection
-------------

Tag SNPs were selected from the Han Chinese data in Haploview (<http://hapmap.ncbi.nlm.nih.gov/>). Other functional or well-studied SNPs were simultaneously selected based on previous studies ([@ref-41], [@ref-42]) that have documented associations between SNPs in the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster and lipid levels. The minor allele frequency (MAF) criterion for these SNPs was a MAF \>0.05 in the Chinese Han population. Finally, six SNPs were included in this study: *APOA1* rs5072, *APOC3* rs5128, *APOA4* rs5104, *APOA5* rs651821, *ZPR1* rs2075294 and *BUD13* rs10488698.

DNA extraction and genotyping
-----------------------------

Genomic DNA was extracted from peripheral blood lymphocytes following the protocols provided with a commercial DNA extraction kit (JiuNa Biology, Hangzhou, China). Genotyping of each SNP was performed via MALDI-TOF-MS (Sequenom, San Diego, CA, USA) with a MassARRAY system. Completed genotyping reactions were dispensed onto a 384-well SpectroCHIP using a MassARRAY nanodispenser (Sequenom, San Diego, CA, USA).

The detection rates for the six SNPs were 99.7%, 99.6%, 95.8%, 99.6%, 99.8% and 99.8% (for *APOA1* rs5072, *APOC3* rs5128, *APOA4* rs5104, *APOA5* rs651821, *ZPR1* rs2075294 and *BUD13* rs10488698, respectively).

Statistical analysis
--------------------

Continuous variables with a normal distribution were summarized as the mean ± standard deviation and compared by Student's *t*-test. The Chi-square test was used to check whether the genotype and allele distributions of the six SNPs were significantly different between males and females. For each SNP, the Hardy--Weinberg equilibrium (HWE) was calculated with the goodness-of-fit Chi-square test. *P* \< 0.05 was considered statistically significant. Binary logistic regression analysis was used to detect associations between the genotypes of the six SNPs in the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster (in the Dominant Model) and dyslipidemia adjusted for sex (adjusted only in the overall group), age, body mass index (BMI) and waist circumference in the overall, male and female groups. We set hypercholesterolemia, hypertriglyceridemia, high LDL cholesterolemia and reduced HDL cholesterolemia as dependent variables, while genotypes, sex (only in the overall group), age, BMI and waist circumference were set as independent variables and entered as method. The strength of any evident association was explored by calculating odds ratios (OR) together with their 95% confidence intervals (CI), and *P-*values of no more than 0.008 after Bonferroni Correction were considered statistically significant. All analyses were conducted using SPSS 24.0. Linkage disequilibrium (LD) and haplotype analyses were performed with the SNPStats program (<https://www.snpstats.net/start.htm>) ([@ref-29]) and Haploview software ([@ref-5]).

Results
=======

Subject characteristics and distributions of genotype and allele
----------------------------------------------------------------

The baseline characteristics of the subjects stratified by genders were shown in [Table 1](#table-1){ref-type="table"}. No difference was observed between males and females in terms of BMI, but the average age and waist circumference were greater in males than females. In addition to the percentage of subjects with hypercholesterolemia, there were significant differences in the percentages of subjects with hypertriglyceridemia, high LDL, reduced HDL and dyslipidemia between males and females. There were 2,264 participants without dyslipidemia while the numbers of participants with one to four type of dyslipidemia were 763, 623, 184 and 16, respectively. The top five types of dyslipidemia (and the number of participants with each type) were as follows: hypertriglyceridemia (425), hypertriglyceridemia + reduced HDL cholesterolemia (397), reduced HDL cholesterolemia (220), hypercholesterolemia + high LDL cholesterolemia (126) and hypertriglyceridemia + hypercholesterolemia + high LDL cholesterolemia (107).
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###### Basic characteristics and distribution of dyslipidemia of included subjects.
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  Characteristics                 Total (*n* = 3,850)   Male (*n* = 1,927)   Female (*n* = 1,923)   *P*
  ------------------------------- --------------------- -------------------- ---------------------- -------------
  Age (year)                      49.54 (9.58)          49.93 (9.75)         49.16 (9.39)           **0.013**
  Waist (cm)                      82.73 (11.22)         84.74 (11.25)        80.72 (10.83)          **\<0.001**
  BMI (kg/m^2^)                   24.40 (3.96)          24.38 (3.93)         24.42 (4.00)           0.734
  Hypertriglyceridemia, *n* (%)   1,110 (28.8)          664 (34.5)           446 (23.2)             **\<0.001**
  Hypercholesterolemia, *n* (%)   444 (11.5)            214 (11.1)           230 (12.0)             0.406
  High LDL, *n* (%)               352 (9.1)             145 (7.5)            207 (10.8)             **\<0.001**
  Reduced HDL, *n* (%)            719 (18.7)            450 (23.4)           269 (14.0)             **\<0.001**
  Dyslipidemia, *n* (%)           1,586 (41.2)          880 (45.7)           706 (36.7)             **\<0.001**

**Notes:**

Means (standard deviation) for age, waist and BMI, a *P*-value in bold indicated differences were significant between males and females (*P* \< 0.05).

BMI, body mass index.

The genotype distributions of the six SNPs in the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster conformed to HWE in the overall group ([Table S1](#supp-1){ref-type="supplementary-material"}). The allele distribution of one SNP (rs651821) was different between males and females, and the genotype and allele distributions of the six SNPs were shown in [Table S1](#supp-1){ref-type="supplementary-material"}. Genotype distributions and allele frequencies of dyslipidemia and normal groups were shown in [Table S2](#supp-2){ref-type="supplementary-material"}.

Association between SNPs and dyslipidemia
-----------------------------------------

In the overall group, logistic regression analysis revealed that dyslipidemia was associated with three SNPs (rs5072, rs5104 and rs651821) after adjusting for sex, age, BMI and waist circumference ([Table 2](#table-2){ref-type="table"}). In the male group, rs651821 was found to be associated with hypertriglyceridemia (OR = 1.78, 95% CI \[1.41--2.26\]) and low-HDL cholesterolemia (OR = 1.61, 95% CI \[1.27--2.05\]). Similar results were observed in the female group. However, we found that rs5072 was associated with hypertriglyceridemia (OR = 1.39, 95% CI \[1.09--1.76\]) in the female group ([Table 2](#table-2){ref-type="table"}). The association between the numbers of risk alleles and dyslipidemia was shown in [Table S3](#supp-3){ref-type="supplementary-material"}.
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###### Association between genotypes of the six SNPs and dyslipidemia stratified by genders.
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  SNPs                 Hypertriglyceridemia (*n* = 1,110)   Hypercholesterolemia (*n* = 444)   High LDL (*n* = 352)   Reduced HDL (*n* = 719)
  -------------------- ------------------------------------ ---------------------------------- ---------------------- -------------------------
  Overall                                                                                                             
  *APOA1*-rs5072                                                                                                      
  TC + TT vs CC        **1.36 (1.15--1.60)**                1.02 (0.83--1.25)                  0.84 (0.67--1.05)      1.16 (0.97--1.39)
  *APOA4*-rs5104                                                                                                      
  GA + GG vs AA        1.25 (1.06--1.48)                    1.01 (0.82--1.25)                  0.82 (0.65--1.03)      1.24 (1.03--1.49)
  *APOC3*-rs5128                                                                                                      
  GC + CC vs GG        **1.33 (1.13--1.57)**                1.02 (0.83--1.25)                  0.84 (0.67--1.05)      1.16 (0.97--1.39)
  *APOA5*-rs651821                                                                                                    
  CT + CC vs TT        **2.01 (1.71--2.38)**                1.23 (1.00--1.50)                  1.00 (0.80--1.25)      **1.90 (1.59--2.28)**
  *ZPR1*-rs2075294                                                                                                    
  GT + TT vs GG        0.89 (0.74--1.07)                    0.83 (0.66--1.05)                  0.87 (0.67--1.13)      0.91 (0.75--1.12)
  *BUD13*-rs10488698                                                                                                  
  CT + TT vs CC        0.75 (0.59--0.95)                    1.02 (0.77--1.35)                  0.99 (0.73--1.36)      0.70 (0.54--0.92)
  Males                                                                                                               
  *APOA1*-rs5072                                                                                                      
  TC + TT vs CC        1.34 (1.06--1.69)                    1.16 (0.86--1.56)                  0.81 (0.58--1.15)      1.19 (0.94--1.52)
  *APOA4*-rs5104                                                                                                      
  GA + GG vs AA        1.28 (1.01--1.63)                    1.14 (0.84--1.54)                  0.77 (0.54--1.09)      1.28 (1.00--1.63)
  *APOC3*-rs5128                                                                                                      
  GC + CC vs GG        1.31 (1.04--1.65)                    1.20 (0.89--1.62)                  0.85 (0.60--1.20)      1.16 (0.91--1.47)
  *APOA5*-rs651821                                                                                                    
  CT + CC vs TT        **1.78 (1.41--2.26)**                1.16 (0.86--1.56)                  0.77 (0.55--1.10)      **1.61 (1.27--2.05)**
  *ZPR1*-rs2075294                                                                                                    
  GT + TT vs GG        0.99 (0.76--1.30)                    0.68 (0.48--0.98)                  0.61 (0.39--0.95)      1.03 (0.78--1.35)
  *BUD13*-rs10488698                                                                                                  
  CT + TT vs CC        0.87 (0.62--1.20)                    1.24 (0.84--1.83)                  1.68 (1.10--2.57)      0.74 (0.52--1.05)
  Females                                                                                                             
  *APOA1*-rs5072                                                                                                      
  TC + TT vs CC        **1.39 (1.09--1.76)**                0.92 (0.69--1.22)                  0.87 (0.65--1.17)      1.10 (0.84--1.45)
  *APOA4*-rs5104                                                                                                      
  GA + GG vs AA        1.22 (0.96--1.55)                    0.91 (0.68--1.22)                  0.86 (0.64--1.17)      1.18 (0.89--1.55)
  *APOC3*-rs5128                                                                                                      
  GC + CC vs GG        1.37 (1.08--1.74)                    0.89 (0.67--1.18)                  0.85 (0.63--1.15)      1.14 (0.87--1.50)
  *APOA5*-rs651821                                                                                                    
  CT + CC vs TT        **2.26 (1.77--2.88)**                1.27 (0.95--1.69)                  1.19 (0.89--1.60)      **2.29 (1.73--3.04)**
  *ZPR1*-rs2075294                                                                                                    
  GT + TT vs GG        0.82 (0.63--1.07)                    1.01 (0.73--1.38)                  1.11 (0.80--1.53)      0.78 (0.57--1.07)
  *BUD13*-rs10488698                                                                                                  
  CT + TT vs CC        0.66 (0.46--0.94)                    0.94 (0.62--1.42)                  0.64 (0.39--1.03)      0.67 (0.44--1.02)

**Notes:**

ORs (95% CI) were shown in bold if corresponding *P*-values were no more than 0.008 (0.05/6). The genetic model in this association analysis was the Dominant Model.

SNP, single nucleotide polymorphism; BMI, body mass index; OR, odds ratio; CI, confidence interval.

ORs and 95% CI were adjusted for sex, age, waist circumference and BMI in the overall group; ORs and 95% CI were adjusted for age, waist circumference and BMI in the male and female groups.

Linkage disequilibrium and haplotype analyses
---------------------------------------------

The pattern of pairwise LD between the SNPs of the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster was shown in [Fig. 1](#fig-1){ref-type="fig"}. Rs10488698, rs2075294 and rs651821 were located in block 1, while rs5104, rs5128 and rs5072 were located in block 2 after choosing the cut-off value of 0.75 for *D*′. The haplotype analysis results were shown in [Table 3](#table-3){ref-type="table"}. People carrying haplotypes 2 and 3 presented an increased risk of dyslipidemia in the total sample and the female and male groups. The association between haplotypes in blocks and different types of dyslipidemia stratified by sexes was explored. We found that subjects with haplotype CGC of block 1 exhibited a higher risk of developing hypertriglyceridemia and reduced HDL cholesterolemia in both sexes. In males, subjects carrying haplotype GCT of block 2 presented a higher risk of developing hypertriglyceridemia and reduced HDL cholesterolemia; however, these results were not observed in females. Details were shown in [Table S4](#supp-4){ref-type="supplementary-material"}.

![Linkage disequilibrium analysis of six SNPs.\
The value of *D′* chosen as cut-off for linkage disequilibrium was 0.75.](peerj-07-6175-g001){#fig-1}
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###### Association between *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster haplotypes and the risk for dyslipidemia.
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  Haplotype                               SNPs[^a^](#table-3fn2){ref-type="fn"}   Number of variants   Frequency   Adjusted OR (95% CI)[^b^](#table-3fn3){ref-type="fn"}   *P*[^c^](#table-3fn4){ref-type="fn"}                                         
  --------------------------------------- --------------------------------------- -------------------- ----------- ------------------------------------------------------- -------------------------------------- ---- --- -------- ------------------- --------------
  Overall                                                                                                                                                                                                                                               
  1                                       C                                       A                    G           T                                                       G                                      C    0   0.3867   1.00                --
  2                                       T                                       G                    C           C                                                       G                                      C    4   0.1297   1.63 (1.36--1.96)   **\<0.0001**
  3                                       C                                       A                    G           C                                                       G                                      C    1   0.1145   1.65 (1.35--2.02)   **\<0.0001**
  4                                       C                                       A                    G           T                                                       T                                      C    1   0.0673   1.02 (0.79--1.32)   0.86
  5                                       C                                       A                    G           T                                                       G                                      T    1   0.0644   0.83 (0.65--1.06)   0.13
  6                                       T                                       G                    C           T                                                       T                                      C    4   0.0615   1.05 (0.80--1.37)   0.75
  7                                       T                                       G                    C           T                                                       G                                      C    3   0.0614   0.92 (0.69--1.23)   0.59
  8                                       T                                       A                    C           T                                                       G                                      C    2   0.0251   0.61 (0.38--0.99)   0.047
  9                                       C                                       G                    G           C                                                       G                                      C    2   0.0187   1.43 (0.87--2.38)   0.16
  10                                      C                                       G                    G           T                                                       G                                      C    1   0.0153   0.87 (0.46--1.62)   0.66
  11                                      T                                       A                    C           C                                                       G                                      C    3   0.0119   2.35 (1.22--4.51)   0.01
  12                                      C                                       G                    G           T                                                       T                                      C    2   0.0119   1.54 (0.86--2.75)   0.15
  Rare[^d^](#table-3fn5){ref-type="fn"}   --                                      --                   --          --                                                      --                                     --       0.0316   1.20 (0.83--1.75)   0.33
  Males                                                                                                                                                                                                                                                 
  1                                       C                                       A                    G           T                                                       G                                      C    0   0.3813   1.00                --
  2                                       T                                       G                    C           C                                                       G                                      C    4   0.1396   1.43 (1.10--1.87)   **0.0078**
  3                                       C                                       A                    G           C                                                       G                                      C    1   0.1200   1.56 (1.16--2.10)   **0.003**
  4                                       C                                       A                    G           T                                                       G                                      T    1   0.0680   0.90 (0.64--1.28)   0.57
  5                                       C                                       A                    G           T                                                       T                                      C    1   0.0626   0.97 (0.65--1.44)   0.88
  6                                       T                                       G                    C           T                                                       G                                      C    3   0.0606   1.20 (0.79--1.81)   0.39
  7                                       T                                       G                    C           T                                                       T                                      C    4   0.0592   1.15 (0.77--1.73)   0.50
  8                                       T                                       A                    C           T                                                       G                                      C    2   0.0269   0.69 (0.36--1.32)   0.26
  9                                       C                                       G                    G           C                                                       G                                      C    2   0.0162   0.88 (0.36--2.11)   0.77
  10                                      C                                       G                    G           T                                                       G                                      C    1   0.0153   0.62 (0.25--1.53)   0.30
  11                                      C                                       G                    G           T                                                       T                                      C    2   0.0108   1.55 (0.61--3.95)   0.36
  Rare[^d^](#table-3fn5){ref-type="fn"}   --                                      --                   --          --                                                      --                                     --       0.0395   1.13 (0.69--1.88)   0.62
  Females                                                                                                                                                                                                                                               
  1                                       C                                       A                    G           T                                                       G                                      C    0   0.3932   1.00                --
  2                                       T                                       G                    C           C                                                       G                                      C    4   0.1199   1.89 (1.45--2.45)   **\<0.0001**
  3                                       C                                       A                    G           C                                                       G                                      C    1   0.1084   1.71 (1.29--2.28)   **2*e*-04**
  4                                       C                                       A                    G           T                                                       T                                      C    1   0.0720   1.12 (0.80--1.59)   0.50
  5                                       T                                       G                    C           T                                                       T                                      C    3   0.0638   1.04 (0.72--1.50)   0.85
  6                                       T                                       G                    C           T                                                       G                                      C    3   0.0620   0.68 (0.44--1.06)   0.09
  7                                       C                                       A                    G           T                                                       G                                      T    1   0.0602   0.80 (0.55--1.15)   0.23
  8                                       T                                       A                    C           T                                                       G                                      C    2   0.0237   0.67 (0.33--1.35)   0.26
  9                                       C                                       G                    G           C                                                       G                                      C    2   0.0216   1.94 (1.05--3.58)   0.033
  10                                      C                                       G                    G           T                                                       G                                      C    1   0.0149   1.39 (0.58--3.32)   0.45
  11                                      T                                       A                    C           C                                                       G                                      C    3   0.0144   2.76 (1.30--5.85)   0.0081
  12                                      C                                       G                    G           T                                                       T                                      C    2   0.0129   1.48 (0.69--3.16)   0.31
  13                                      T                                       G                    C           T                                                       G                                      T    4   0.0115   1.52 (0.61--3.75)   0.37
  Rare[^d^](#table-3fn5){ref-type="fn"}   --                                      --                   --          --                                                      --                                     --       0.0214   1.16 (0.58--2.30)   0.67

**Notes:**

SNP, single nucleotide polymorphism; BMI, body mass index; OR, odds ratio; CI, confidence interval.

SNPs are as follows: 1, rs5072; 2, rs5104; 3, rs5128; 4, rs651821; 5, rs2075294; 6, rs10488698.

ORs were adjusted for sex, age, BMI and waist circumference in the overall group and were adjusted for age, BMI and waist circumference in males and females.

*P*-values \> 0.008 were considered to be significant after Bonferroni correction and were presented in bold.

Rare: haplotypes with frequencies \<0.01.

Discussion
==========

The study applied a large sample design to study the association between the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster gene polymorphisms and dyslipidemia. The participants in this study were enrolled from a representative community-based population. To the best of our knowledge, this is the first study to analyze the association of this gene cluster with dyslipidemia in a sex-specific pattern in northeast China.

The *APOA1/C3/A4/A5* gene cluster is a well-studied gene cluster. [@ref-32] found that there was a significant association between *APOA1* rs5072 and TG in Mexican children, and in an Indian study [@ref-24] concluded that rs5072 was also associated with increased TG; both of these findings were similar to our results. [@ref-24] found that the genotypic and allelic frequencies of rs5072 exhibited no significant differences between cases and controls; however, our study indicated that there was an association between them in females. One explanation for the difference between these two studies could be that they were conducted in people of different ethnicities and ages. A recent exome-wide association study ([@ref-44]) performed in a Japanese population indicated that *APOA4* rs5104 located in this gene was associated with the serum TG concentration. A GWAS conducted in Chinese people ([@ref-49]) showed that rs651821 presented a strong association with TG levels. [@ref-8] drew the conclusion that subjects carrying the variant allele of this SNP exhibited a higher risk of developing low-HDL cholesterolemia than noncarriers in both genders in Koreans, which was consistent with our findings. In our study, haplotype analysis showed that participants carrying the CGC haplotype of block 1 presented a higher risk of developing hypertriglyceridemia (OR = 1.76, 95% CI \[1.59--1.96\]) and reduced HDL (OR = 1.80, 95% CI \[1.59--2.03\]) than those carrying the CGT haplotype, which revealed that the T allele of rs651821 was associated with a higher risk of hypertriglyceridemia and reduced HDL. The MAFs of rs5072, rs5128, rs5104 and rs651821 in our study were 0.3060, 0.2966, 0.2995 and 0.2406, respectively. These results were similar to the frequencies identified in the southern Han Chinese population in the 1,000 Genomes Project, which were 0.3190, 0.3190, 0.3571 and 0.2714. Compared with the frequencies observed in American subjects (0.0656, 0.0492, 0.1311 and 0.1639), British subjects (0.1099, 0.1209, 0.1648 and 0.0714) and other ethnicities, the frequencies determined in our study were markedly different. Ethnicity may be critically important in studying the association between SNPs and dyslipidemia. We used Polyphen to predict the influence of two missense mutations (*APOA4* rs5014 and *BUD13* rs10188698) on the resultant proteins and found that there was no significant influence on protein function. We also observed that these two SNPs were not associated with any types of dyslipidemia.

At present, studies on *BUD13-ZPR1* gene polymorphisms focus on the association with lipid-related diseases. *BUD13* and *ZPR1* were found to be associated across anatomical categories of coronary artery disease in an Indian study ([@ref-23]). Another study ([@ref-18]) performed in a Taiwanese population indicated that *BUD13* may contribute to the risk of MetS, and *BUD13* rs623908 was shown to be significantly associated with high TG, low HDL and HDL levels. Among Chinese individuals ([@ref-43]), a strong association between *BUD13-ZPR1* rs964184 and coronary heart disease was found, and both gender and age had great impacts on the association of the rs964184 polymorphism with coronary heart disease. Another study ([@ref-35]) indicated that rs964184 was significantly associated with the prevalence of MetS. In addition, there have been studies showing that that *ZPR1* contributed to the risk of type 2 diabetes mellitus ([@ref-16]; [@ref-34]). Due to the association of these two genes with lipid-related diseases, we conjecture that *BUD13* and *ZPR1* gene polymorphisms may contribute to the risk of dyslipidemia.

In our study, we obtained the novel finding of sex-specific differences between the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster gene polymorphisms and dyslipidemia. These differences could be partially explained by differences in sex between males and females. Menopause could change the lipid profile by reducing HDL-C and increasing TG, TC and LDL-C ([@ref-27]). However, after menopause, healthy females were prone to become more insulin resistant and gain total body and intra-abdominal fat ([@ref-20]). Additionally, females with polycystic ovary syndrome usually become overweight or obese, especially abdominally obese ([@ref-40]). Accumulation of body and central fat and decreased insulin resistance are associated with TG, HDL-C and LDL-C and may therefore alter lipid homeostasis, respectively ([@ref-12]). Consequently, mechanisms underlying sex-specific differences between the gene cluster and dyslipidemia are complex and should be further studied. We also found that the associations of the SNPs with dyslipidemia were different when the total sample, males and females were considered separately. We speculated that these associations may be influenced by sex and *P*-values we set, since some *P-*values were between 0.008 and 0.05. There are some limitations of our study that must be recognized. In each gene, we selected only one tag SNP with a MAF \>5% reported in published articles. We may have ignored some SNPs with low MAFs or important functions in the *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster. In addition, dyslipidemia is influenced not only by genetic factors but also by diet, exercise and other environmental factors. We adjusted only sex, age, BMI and waist circumference in our study. Consequently, more environmental factors need to be recorded and adjusted in future studies, and the effects and mechanisms of SNPs in relation to gene expression and protein expression warrant further study.

Conclusion
==========

In conclusion, we analyzed and assessed the association between *APOA1/C3/A4/A5-ZPR1-BUD13* gene cluster gene polymorphisms and dyslipidemia between sexes. We not only obtained several results consistent with those reported based on previous studies but also found one SNP (rs5072) was different between males and females, providing new insight into the mechanisms of dyslipidemia in different genders.
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